Wall Street analysts forecast that Galmed Pharmaceuticals (NASDAQ:GLMD) will announce ($0.21) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Galmed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.19). Galmed Pharmaceuticals posted earnings per share of ($0.26) during the same quarter last year, which would indicate a positive year-over-year growth rate of 19.2%. The company is expected to issue its next quarterly earnings report on Monday, May 21st.
On average, analysts expect that Galmed Pharmaceuticals will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.41). For the next fiscal year, analysts expect that the firm will post earnings of ($0.71) per share, with EPS estimates ranging from ($1.62) to $0.49. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.04). The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Galmed Pharmaceuticals had a negative return on equity of 133.50% and a negative net margin of 1,133.55%.
A number of research analysts recently issued reports on the company. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Maxim Group upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Thursday, March 15th. Zacks Investment Research downgraded Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Finally, HC Wainwright increased their price objective on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Galmed Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $20.40.
NASDAQ:GLMD opened at $6.24 on Wednesday. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $12.22.
A number of hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC grew its stake in Galmed Pharmaceuticals by 18.2% in the fourth quarter. 683 Capital Management LLC now owns 649,295 shares of the biopharmaceutical company’s stock valued at $5,941,000 after purchasing an additional 100,000 shares in the last quarter. Meitav Dash Investments Ltd. bought a new position in Galmed Pharmaceuticals in the fourth quarter valued at approximately $4,357,000. Park West Asset Management LLC grew its stake in Galmed Pharmaceuticals by 4.4% in the fourth quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after purchasing an additional 12,347 shares in the last quarter. Sphera Funds Management LTD. bought a new position in Galmed Pharmaceuticals in the fourth quarter valued at approximately $2,164,000. Finally, J. Goldman & Co LP bought a new position in Galmed Pharmaceuticals in the fourth quarter valued at approximately $569,000. Hedge funds and other institutional investors own 17.69% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Galmed Pharmaceuticals (GLMD) Expected to Post Earnings of -$0.21 Per Share” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/16/galmed-pharmaceuticals-glmd-expected-to-post-earnings-of-0-21-per-share.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.